Technical Perspectives on Biotech Stocks -- BioCryst Pharma, BioDelivery Sciences, BioLine Rx, and BioTime
NEW YORK, Feb. 20, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on BCRX, BDSI, BLRX, and BTX which can be accessed for free by signing up to www.wallstequities.com/registration. Ahead of today's trading session, WallStEquities.com follows BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), BioDelivery Sciences International Inc. (NASDAQ: BDSI), BioLine Rx Ltd (NASDAQ: BLRX), and BioTime Inc. (NYSE AMER: BTX). These companies belong to the Biotech space, which focuses on novel drug development and clinical research aimed at treating diseases and medical conditions. All you have to do is sign up today for this free limited time offer by clicking the link below.
www.wallstequities.com/registration
BioCryst Pharmaceuticals
Durham, North Carolina headquartered BioCryst Pharmaceuticals Inc.'s stock finished last Friday's session 1.85% higher at $4.96. A total volume of 1.53 million shares was traded, which was above their three months average volume of 1.27 million shares. The Company's shares have advanced 8.06% over the previous three months. The stock is trading below its 50-day moving average by 2.12%. Additionally, shares of BioCryst Pharma, which designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases, have a Relative Strength Index (RSI) of 51.07.
On January 22nd, 2018, BioCryst Pharma (BCRX) and Idera Pharmaceuticals, Inc. (IDRA), announced that they have signed a definitive merger agreement to form a new enterprise focused on the development and commercialization of medicines to serve more patients suffering from rare diseases. The combined company will be renamed upon closing and will be led by Vincent Milano, CEO of IDRA, who will also serve as a member of the Board. BCRX'S Chairman, Robert Ingram, will be Chairman of the Board of the combined company. Get the full research report on BCRX for free by clicking below at:
www.wallstequities.com/registration/?symbol=BCRX
BioDelivery Sciences International
On Friday, shares in Raleigh, North Carolina headquartered BioDelivery Sciences International Inc. ended the session flat at $2.10. The stock recorded a trading volume of 492,066 shares. The Company's shares have gained 12.00% over the past year. The stock is trading 19.91% below its 50-day moving average. Moreover, shares of BioDelivery Sciences, which engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction, have an RSI of 32.88.
On January 26th, 2018, research firm Seaport Global Securities initiated a 'Buy' rating on the Company's stock, with a target price of $5 per share.
On February 06th, 2018, BioDelivery Sciences announced that it has entered into a Settlement Agreement with Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals Industries, Ltd. ("Teva") that resolves the Company's previously reported BELBUCA® (buprenorphine) buccal film (CIII), patent litigation against Teva pending in the US District Court for the District of Delaware. Access the free research report on BDSI now by signing up at:
www.wallstequities.com/registration/?symbol=BDSI
BioLine Rx
Jerusalem, Israel headquartered BioLine Rx Ltd's shares closed the session flat at $1.01 with a total trading volume of 172,463 shares. The stock has gained 4.83% over the previous three months. The stock is trading 1.08% below their 200-day moving average. Shares of BioLine Rx, which engages in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs, have an RSI of 46.28.
On January 23rd, 2018, BioLine Rx announced the publication of data showing that BL-8040, its lead oncology platform, augments the ability of the immune system to fight cancer by increasing the infiltration of anti-tumor-specific T-cells into the tumor microenvironment, resulting in decreased tumor growth and prolonged survival in a murine model of cancer. Are you already registered with Wall St. Equities? Do so now for free, and get the report on BLRX at:
www.wallstequities.com/registration/?symbol=BLRX
BioTime
Last Friday at the close, shares in Alameda, California-based BioTime Inc. recorded a trading volume of 314,175 shares. The stock ended the session 1.89% lower at $2.60. The Company's shares have advanced 4.42% over the previous three months. The stock is trading above its 50-day moving average by 1.35%. Furthermore, shares of BioTime have an RSI of 45.80.
On February 02nd, 2018, research firm Lake Street initiated a 'Buy' rating on the Company's stock, with a target price of $8 per share.
On February 15th, 2018, BioTime announced that two abstracts have been accepted and will be presented at the upcoming Association for Research in Vision and Ophthalmology (ARVO) meeting, which will take place at the Hawaii Convention Center in Honolulu: (i) the OpRegen® Poster Presentation is scheduled for April 29th, 2018 from 8:15 a.m. to 10:00 a.m. local Hawaii Time; and (ii) the Vision Restoration Paper Presentation is scheduled for May 01st, 2018 from 12:15 p.m. to 12:30 p.m. local Hawaii Time. Aspiring Member, please take a moment to register below for your free research report on BTX at:
www.wallstequities.com/registration/?symbol=BTX
--
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
https://wallstequities.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: +21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Wall St. Equities
Share this article